Bristol Myers Squibb

BREYANZI

Manufacturer:

Bristol Myers Squibb

Breyanzi HCPCS:

Q2054

HCPCS Code Descriptor:

Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

Breyanzi NDCs:

73153-0900-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Breyanzi:

BREYANZI is an Oncology drug manufactured by Bristol Myers Squibb and administered via the Intravenous route of administration. The Q Code: Q2054 is aligned to the drug BREYANZI.

ACCESS PRICING AND MORE BY REGISTERING

Q2054 Added Date:

October 1, 2021

Q2054 Effective Date:

October 1, 2021

Q2054 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Breyanzi billing and coding information.
Breyanzi patient assistance information can be found through Cell Therapy 360 at the URL: https://www.celltherapy360.com/patients/
BREYANZI prescribing information can be found at the link below:
Information regarding BREYANZI’s side effects can be found at MedlinePlus